89bio

89bio Total Assets

Delisted

The Total Assets of 89bio (ETNB) as of Nov 8, 2026 is 478.69 M USD. In the previous year, Total Assets was 596.27 M USD — a change of -19.72% (lower).

Total Assets

478.69 MUSD

YoY

-19.72%

Last updated:

Total Assets of 89bio is 2024 478.69 M USD. Total Assets of 89bio was 2023 596.27 M USD. It decreases by -19.72% lower compared to the previous year.

The 89bio Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
11.37 M USD
Jan 1, 2019
95.55 M USD
Jan 1, 2020
211.07 M USD
Jan 1, 2021
162.42 M USD
Jan 1, 2022
196.82 M USD
Jan 1, 2023
596.27 M USD
Jan 1, 2024
478.69 M USD
The 89bio Total Assets history
YEARTotal AssetsYoY
478.69 MUSD-19.72%
596.27 MUSD+202.95%
196.82 MUSD+21.18%
162.42 MUSD-23.05%
211.07 MUSD+120.90%
95.55 MUSD+740.47%
11.37 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

89bio Stock analysis

What does 89bio do? 89Bio Inc is an emerging biopharmaceutical company focused on developing drugs to treat metabolic and liver diseases. The company was founded in 2018 and is headquartered in San Francisco, California. 89Bio's business model is based on utilizing innovative science and technology to develop novel and effective therapeutic options for diseases that are currently only limitedly treatable. The company has assembled an interdisciplinary team of scientists, physicians, and entrepreneurs with extensive experience in the pharmaceutical industry. 89Bio has two main divisions: Endocrine and Liver Diseases. In the field of Endocrine Diseases, the company has developed a platform technology based on the binding of human proteins with high affinity and specificity. This technology aims to treat hormone deficiencies in patients with certain endocrine disorders. An example of the application of this technology is 89Bio's leading product, BIO89-100, which is currently in development for the treatment of hypoparathyroidism. The second division of 89Bio is Liver Diseases. The company has developed a pipeline of drug candidates for liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These diseases are a growing public health concern worldwide as they are associated with obesity, diabetes, and other metabolic disorders. The leading product in this pipeline is BIO89-1000, which aims to improve liver function by activating a specific group of receptors in the body. In recent years, 89Bio has established strong partnerships with leading companies in the pharmaceutical industry to accelerate its research and development. The company has also received funding from renowned global investors to support its growth and expansion. Overall, 89Bio Inc has a promising future as it focuses on developing therapeutic options for serious diseases that are currently inadequately treated. The company has a strong foundation in research and technology, as well as the experience of its leadership team and partnerships. With its new and innovative approaches, 89Bio can make a sustainable contribution to improving healthcare and patient well-being. 89bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 89bio stock

Total Assets of 89bio is 478.69 M USD in 2024.

Total Assets of 89bio changed from 596.27 M USD to 478.69 M USD, representing a -19.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets 89bio since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's 89bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — 89bio

All Key Metrics — 89bio